Exelixis, Inc. (EXEL) CEO Michael Morrissey on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
Exelixis, Inc. (NASDAQ:EXELCompany ParticipantsSusan Hubbard - EVP, Public Affairs & IRMichael Morrissey - CEO, President & DirectorChristopher Senner - EVP & CFOPatrick Haley - EVP, CommercialVicki Goodman - EVP, Product Development & Medical Affairs and Chief Medical OfficerPeter Lamb - EVP, Scientific Strategy & Chief Scientific OfficerConference Call ParticipantsJason Gerberry - Bank of America Merrill LynchMichael Schmidt - Guggenheim SecuritiesAndy Hsieh - William Blair & CompanyPeter Lawson - Barclays BankJay Olson - OppenheimerEtzer Darout - BMO Capital Yaron Werber - Cowen and CompanyOperatorGood day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2022 Financial Results Conference Call. My name is Sarah, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please pr
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024Business Wire
- Global Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90% [Yahoo! Finance]Yahoo! Finance
- Exelixis slips as Barclays downgrades on lack of catalysts [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 2/6/24 - Beat
EXEL
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- EXEL's page on the SEC website